Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the Potential of Chemomabs
Barbara Lindheim Wadi Mor Strategic Communications Chemomab Therapeutics Ltd Prnewswire Chemomab Therapeutics Ltd European Union
Source: eagletribune.com